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Inhibition of nitric oxide synthase reverses changes in perito- functional modifications observed during acute peritoni-
neal permeability in a rat model of acute peritonitis. tis include a major increase in permeability for small
Background. Acute peritonitis is the most frequent compli- solutes and glucose, leading to a faster than normal dissi-cation of peritoneal dialysis (PD), and nitric oxide (NO) is
pation of the osmotic gradient, a decrease of free-waterthought to play a role in the structural and permeability changes
permeability, and a loss of ultrafiltration (UF) [2]. Fun-observed in this condition. We have used a combination of
expression, enzymatic and pharmacological studies to substan- damentally, the transport of solutes across the perito-
tiate the potential role(s) played by NO during peritonitis. neum during PD depends on the intrinsic permeability of
Methods. The peritoneal equilibration test was performed
the membrane to each solute and the effective peritonealin control rats and rats with acute peritonitis (originating from
surface area (EPSA), characterized by the number ofskin flora), using standard dialysate supplemented or not with
the NO synthase (NOS) inhibitor NG-nitro-l-arginine methyl perfused capillaries within the peritoneum [3]. In view
ester (L-NAME). In parallel, peritoneal NOS enzymatic activi- of its role in the regulation of vascular tone and perme-
ties were measured and expression studies for NOS isoforms
ability [4] and its interference with growth factors toand S-nitrosocysteine reactivity performed in the peritoneum.
promote angiogenesis [5, 6], nitric oxide (NO) is increas-Results. In comparison with controls, rats with acute perito-
nitis were characterized by inflammatory changes, increased ingly considered as a key mediator of peritoneal perme-
S-nitrosocysteine immunoreactivity, and increased NOS activi- ability [7–9]. This hypothesis has been supported by
ties in the peritoneum, due to the up-regulation of endothelial experiments showing an increase in peritoneal perme-and inducible NOS. In parallel, rats with acute peritonitis
ability with the NO donor nitroprusside in animal modelsshowed increased permeability for small solutes; decreased
[10] and stable PD patients [11].sodium sieving; loss of ultrafiltration (UF); and increased pro-
tein loss in the dialysate. Addition of L-NAME to the dialysate Nitric oxide is produced from l-arginine by a family
did not induce permeability changes in control rats, but signifi- of NO synthase (NOS) isoforms that are expressed in a
cantly improved UF and reversed permeability modifications
large variety of tissues and cells [4, 6]. The neuronal andin rats with peritonitis. The effect of L-NAME was reflected
endothelial NOS (nNOS and eNOS, respectively) areby a mild but consistent increase in blood pressure during PD
exchange. constitutive isoforms and their activity depends on the in-
Conclusions. Our results demonstrate that local generation tracellular concentration of Ca2. Inducible NOS (iNOS)
of NO, secondary to up-regulation of NOS isoforms, plays an is regulated at a transcriptional level and its activity isimportant role in the regulation of peritoneal permeability
independent of Ca2 [4]. Previous studies have shownduring acute peritonitis in rats. By itself, NOS inhibition im-
proves UF and reverses permeability changes, which might that the three NOS isoforms are expressed in the perito-
offer new therapeutic perspectives in acute peritonitis. neum, and a significant NOS activity can be detected in
peritoneum extracts [7, 9, 12]. The putative role played
by NO during PD across the normal, non-infected perito-Acute peritonitis remains the most frequent and seri-
neum remains controversial. Functional studies in ratsous complication of peritoneal dialysis (PD) [1]. The
have shown that addition of the NOS inhibitor NG-nitro-
l-arginine methyl ester (L-NAME) to the dialysate does
Key words: L-NAME, NO, NOS, dialysis, inflammation, ultrafiltration,
not affect the permeability to small solutes [13]. Additionvascular tone, effective peritoneal surface area, osmosis, free water
permeability. of another NOS inhibitor (NG-monomethyl-l-arginine,
L-NMMA) to the dialysate did not affect peritoneal per-
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of increased NO production [7, 8]. This hypothesis was similar samples from the parietal and visceral perito-
neum were processed for fixation in 4% paraformalde-recently supported by studies demonstrating increased
NOS activity and up-regulation of eNOS and iNOS dur- hyde and protein extraction as previously detailed [9, 12].
All experiments were conducted in accord with localing peritonitis [9].
The aim of this study was to perform a series of func- prescriptions and the NIH Guide for the Care and Use
of Laboratory Animals.tional, biochemical and expression studies to test the
effects of a specific inhibitor of NOS in a well-character-
Immunohistochemistryized rat model, in order to substantiate the role of NO
in the regulation of peritoneal permeability. Immunostaining was performed on 6-m peritoneal
sections embedded in paraffin [9, 16]. After blocking
in 0.3% H2O2 and incubation with 10% normal serum,METHODS
sections were incubated successively for 45 minutes each
Rat model, PD protocol, tissue sampling with well-characterized monoclonal antibodies against
eNOS and iNOS (Transduction Laboratories, Lexing-Adult (8-week-old) male Sprague-Dawley rats (Iffa
Credo, Brussels, Belgium) weighing 279  2 g were ran- ton, KY, USA) [12] or polyclonal antibodies against
S-nitrosocysteine (Alexis, Lausen, Switzerland) [17, 18],domly assigned to control and peritonitis groups. As
previously described [9], peritonitis was induced by non- biotinylated IgG (Vector Laboratories, Burlingame, CA,
USA), and avidin-biotin peroxidase (Vector). Immuno-sterile implantation of a peritoneal catheter under anes-
thesia with SC Nembutal (Sanofi, Brussels; day 1) fol- labeling was visualized using aminoethylcarbazole (Vec-
tor). The specificity of the immunolabeling was con-lowed for six days by a daily two-hour exchange with
15 mL of 1.36% glucose dialysate (DianealR; Baxter, firmed by incubation without primary antibody; with
non-immune mouse or rabbit IgG [9, 16]; or after incuba-Nivelles, Belgium). Both catheter insertion and PD ex-
changes were performed without aseptic precautions, in tion with 0.2% HgCl2 as indicated by the manufacturer
(Alexis). Peritoneal sections stained with hemaluneosineorder to reflect manipulation errors and touch contami-
nation from the skin flora in PD patients [15]. Control or trichrome blue were used for systematic pathological
examinations.rats matched for age and weight were left untouched for
six days. All rats had access to standard chow and tap
Western blot analyseswater ad libitum. On day 7, control and peritonitis rats
were anesthetized to perform a two-hour exchange PD Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and immunoblotting were per-with 15 mL of a 7% glucose dialysate (Dianeal) as de-
scribed previously [9]. The NOS inhibitor L-NAME formed as described [9, 12, 16]. Efficiency of transfer
to nitrocellulose was routinely tested by Ponceau red(Sigma, St. Louis, MO, USA) was added to the dialysate
at concentrations ranging from 2.5 to 10 mmol/L, imme- (Sigma) staining and -actin immunoreactivity (Sigma).
The membranes were blocked for 30 minutes at roomdiately before instillation. Preliminary experiments have
verified that variations of pH and osmolality correspond- temperature, followed by incubation with monoclonal
antibodies raised against eNOS and iNOS at 4C for 16ing to the different L-NAME concentrations in the dialy-
sate [13] do not influence peritoneal parameters in rats. to 18 hours. After washing, the membranes were incu-
bated for one hour at room temperature with peroxidase-Blood pressure was measured by means of a transducer
(Pressure Set Uniflow type 43-600F; Bentley Labora- labeled secondary antibodies (Dako), before visuali-
zation with enhanced chemiluminescence (Amersham,tories Europe, Uden, The Netherlands) implanted in the
carotid artery and connected to a Linearcorder poly- Little Chalfont, UK). Negative controls included incuba-
tion with non-immune mouse IgG (Dako).graph (Ankersmit, Groot-Bijgaarden, Belgium). Blood
and dialysate samples were obtained before (T0), at 30
NOS activity assayminutes (T30), 60 minutes (T60), and 120 minutes (T120)
of dwell time. Creatinine, hematocrit, glucose, sodium, Nitric oxide synthase enzymatic activities were mea-
sured using the l-citrulline assay as described [12].potassium, total protein, osmolality, and enzymatic levels
(transaminases, amylase, lipase, lactic dehydrogenase) Briefly, 25 L of tissue extract (350 g of total protein)
containing 20 mmol/L 3-[(3-cholamidopropyl) dimethyl-were assayed by standard methods; white blood cells
(WBC) in the dialysate (elts/L) were counted in a amminio] 1-propane sulfonate (CHAPS) were added to
200 L of Tris buffer (50 mmol/L, pH 7.4) containingBu¨rker chamber; and dialysate cultures were obtained
[9]. Rats with positive culture and WBC count in the 10 mmol/L dithiothreitol (DTT), 10g/mL calmodulin, 1
mmol/L nicotinamide adenosine dinucleotide phosphatedialysate 1500 elts/L were considered to have perito-
nitis [12]. They represented 75% of the rats that had (NADPH), 4mol/L flavin adenine dinucleotide (FAD),
4 mol/L flavin adenine mononucleotide (FMN), 2been infected according to the protocol. At the end of
the dwell, animals were sacrificed by exsanguination, and mol/L l-arginine, and 103 mCi/mL l-[3H]-arginine
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Table 1. Body weight, hematocrit (Hct), plasma creatinine (PCr) and blood pressure during the dwell in control and peritonitis rats
Systolic blood pressure
Body weight Hct PCr T0 T120 
Rat group N g % mg/dL mm Hg mm Hg %
Control (C) 6 2778 471 0.190.01 1245 827 338
Control  5 mmol/L
L-NAME (C-LA5) 6 2844 491 0.150.02 1126 11315a 316a
Peritonitis (P) 6 2742 451 0.180.03 1438 12217a 1411
Peritonitis  2.5 mmol/L
L-NAME (P-LA2.5) 4 2706 461 0.160.01 1054b 1437 366b
Peritonitis  5 mmol/L
L-NAME (P-LA5) 6 2776 471 0.180.02 1259 1565b 277b
Peritonitis  10 mmol/L
L-NAME (P-LA10) 3 2715 501b 0.160.01 1286 14020 913
Data are mean  SEM.  (%) 	 (T120  T0)/T0.
a P 
 0.05 vs. C
b P 
 0.05 vs. P
(NEN Life Science, Zaventem, Belgium). Assays were cocci, Streptococcus G, and E. coli. In contrast, none of
the cultures obtained from control rats was positive.performed for 30 minutes at 37C and stopped with 2
mL of ice-cold stop buffer [20 mmol/L CH3COONa, There was a significant, inverse correlation between the
magnitude of UF and the severity of peritonitis as re-pH 5.5, containing 2 mmol/L ethylenediaminetetraacetic
acid (EDTA), 0.2 mmol/L egtazic acid (EGTA), and 1 flected by WBC count in the dialysate (P 	 0.03; r 2 	
mmol/L l-citrulline]. L-[3H]-citrulline was separated by 0.31). Body weight, hematocrit, plasma creatinine, and
cation-exchange chromatography (Bio-Rad) and quanti- blood pressure at T0 were similar in control and peritoni-
fied by liquid scintillation. The NOS activity (pmol cit- tis rats (Table 1). Other biological parameters including
rulline/mg protein/min) was determined by subtracting pancreatic and liver enzymes, as well as lactic dehydroge-
counts obtained with or without 1 mmol/L L-NMMA. nase levels, were similar in all groups (data not shown).
Assays were performed with or without Ca2 to measure The addition of L-NAME to the dialysate in control and
total versus the Ca2-independent NOS activities, and peritonitis rats was reflected by an increase in blood
calculate Ca2-dependent NOS activity. Determinations pressure during the exchange, in contrast with the de-
were performed in duplicate on three randomly selected crease observed when PD was performed with the 7%
samples in each group. glucose dialysate (Table 1).
Data analysis Peritoneum structure and reactivity
for S-nitrosocysteineData are presented as mean  SEM. Statistical sig-
nificance was analyzed using the Student t test or one- Morphological examination of the visceral peritoneum
way ANOVA, as appropriate. (Fig. 1) showed that acute peritonitis in rats was reflected
by a massive sub-mesothelial infiltrate of mononuclear
cells, together with edema and vasodilation of the perito-
RESULTS
neal capillaries (Fig. 1 A, B). Acute peritonitis was asso-
Clinical and biological parameters ciated with capillary proliferation, as shown by the in-
creased immunoreactivity for eNOS located in capillaryIn comparison with controls, rats with acute peritonitis
were characterized by (a) decreased UF (1  1 vs. 7.6  endothelium (Fig. 1 C, D). As previously reported [9],
a faint staining for iNOS was detected in mononuclear0.5 mL, P 
 0.001), (b) increased protein loss in the
dialysate (4.7  0.9 vs. 0.8  0.1 g/L, P 
 0.001), (c) cells infiltrating the peritoneum. It must be noted that
the morphological and immunocytochemical observa-cloudy dialysate with an increased WBC count (9844 
3335 vs. 313  35 elts/L, P 	 0.03), and (d) positive tions for NOS isoforms were similar in the visceral and
parietal peritoneum, as illustrated previously [9]. Incuba-dialysate cultures. Analysis of the pathogens responsible
for peritonitis showed a single organism in about 2/3 tion with L-NAME during the dwell did not affect immu-
nostaining for eNOS in the peritoneum (Fig. 1E), theof cases, and multiple germs in others. Gram-positive
organisms were identified in 85% of cases, the remaining specificity of which was verified by absence of staining
with control, non-immune mouse IgG (Fig. 1F). Thebeing gram-negative. The most frequent causative organ-
ism was Staphylococcus aureus, which accounted for 2/3 release of bioactive NO secondary to acute peritonitis
was reflected by an increased immunoreactivity forof the cases, followed by coagulase-negative Staphylo-
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Fig. 1. Effects of acute peritonitis on the peri-
toneum: Morphology and immunostaining.
Hemalun-eosine staining (A and B) and im-
munostaining for eNOS (C and D) in the vis-
ceral peritoneum of control rats (A-C) and
rats with acute peritonitis (B-E). A marked
edema and a massive infiltrate of mononuclear
cells characterize the peritoneum of rats with
peritonitis (B). Immunoreactivity for endo-
thelial nitric oxide synthase (eNOS) is located
in the endothelium lining peritoneal blood
vessels in control rats (C). The staining inten-
sity and the density of capillaries and blood
vessels stained for eNOS are markedly in-
creased in rats with peritonitis (D). The stain-
ing pattern for eNOS is not modified when
rats with peritonitis are treated with 5 mmol/L
L-NAME in the dialysate (E). The specificity
of the immunostaining for eNOS is demon-
strated by the lack of signal when incubation
is performed with control mouse IgG (F ).
Representative sections of the visceral perito-
neum of control rats (G) and rats with peri-
tonitis (H) stained for S-nitrosocysteine. A
major increase in the immunoreactivity is ob-
served in rats with peritonitis, particularly lo-
cated in the mesothelial and endothelial cell
layers. The inset demonstrates the intense im-
munoreactivity for S-nitrosocysteine in the en-
dothelium lining peritoneal capillaries. A simi-
lar staining pattern for S-nitrosocysteine is
observed in the peritoneum of peritonitis rats
that have been treated with L-NAME (I )
(original magnification A-H,350; inset,485;
I, 380).
S-nitrosocysteine in the peritoneum (Fig. 1 G, H), which peritoneum was reflected by a significant increase in total
NOS activity (0.39  0.04 vs. 0.12  0.06 pmol citrul-was particularly concentrated in mesothelial and endo-
thelial cells (Fig. 1H, inset). Incubation with L-NAME line/mg protein/min, P
 0.01), due to both Ca2-depen-
dent and Ca2-independent NOS isoforms (Fig. 2B). Theduring the dwell did not affect the immunostaining for
S-nitrosocysteine (Fig. 1I). presence of NOS inhibitor L-NAME in the peritoneum
extracts during the l-citrulline assay prevented reliable
NOS expression and enzymatic activities in measurements of NOS activities in control and peritoni-
the peritoneum tis rats treated with L-NAME.
Immunoblot analyses confirmed that acute peritonitis
Peritoneal permeabilityinduced a significant up-regulation of both the endothe-
lial (140 kD) and inducible (130 kD) NOS isoforms in Acute peritonitis induced a major increase in perito-
neal permeability for small solutes such as urea (Fig.the peritoneum (Fig. 2A). As previously described [9],
induction of iNOS was variable in intensity, ranging from 3A), a faster glucose absorption from the dialysate (Fig.
3B), and a reduced free-water permeability (as attestedweak to very strong (Fig. 2A, lower band of the gel).
As expected, the up-regulation of NOS isoforms in the by the loss of sodium sieving, Fig. 3C). These changes
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Fig. 2. Effects of acute peritonitis on NOS expression and activity in
the peritoneum. (A) Immunoblot analysis for endothelial (eNOS) and
inducible (iNOS) nitric oxide synthase in peritoneum extracts prepared
from control rats and rats with acute peritonitis (40 g protein/lane, 6
samples in each group). Extracts from bovine aortic endothelial cells
(eNOS) and mouse macrophages (iNOS) were used as positive controls
(lane C). A consistent up-regulation of eNOS (140 kD) is detected in
samples from rats with acute peritonitis. The signal for iNOS (130
kD, lower band of the blot), never detected in control samples, is up-
regulated with variable intensity in rats with acute peritonitis. Note that
the monoclonal antibody against iNOS cross-reacts with eNOS (middle
band at 140 kD) and nNOS (upper band at 155 kD), as previously
reported [12]. (B) NOS enzymatic activities in the peritoneum of control
rats (C) and rats with acute peritonitis (P). Total NOS activity (, in
pmol citrulline/mg protein/min) was assayed by the conversion of l-[3H]-
arginine to L-[3H]-citrulline in the visceral peritoneum. Assays were
performed with or without Ca2, to distinguish between Ca2-dependent
( ) and Ca2-independent () NOS activities. Total NOS activity is
increased (3-fold) in rats with peritonitis. The increased NOS activity
results from both Ca2-dependent and Ca2-independent NOS. *P 

0.05 between peritonitis and control rats.
were reflected by a fall in UF and an increased protein
loss in the dialysate (cf. above, Fig. 4 A, B), as well as
an increased cumulative urea transport during the two
hour dwell (Fig. 4C).
Addition of 5 mmol/L L-NAME to the dialysate in
control rats did not change peritoneal permeability pa-
rameters (Fig. 3), and was not reflected by significant
changes in UF ( vs.  L-NAME: 7.6  0.5 vs. 8.8 
0.5 mL) and protein loss in the dialysate ( vs. 
L-NAME: 0.8 0.1 vs. 1 0.1 g/L). In contrast, addition
of 5 mmol/L L-NAME to the dialysate in rats with acute
Fig. 3. Effect of L-NAME on functional parameters of peritoneal dialysisperitonitis significantly reduced the hyperpermeability
in control and peritonitis rats. The dialysate-to-plasma (D/P) ratio of ureato urea and glucose (Fig. 3 A, B), and significantly im-
(A) and sodium (C), and the progressive removal of glucose from the
proved the dialysate-over-plasma ratio for sodium (Fig. dialysate (D/D0, B) were determined in control rats (, ), and rats with
peritonitis (, ) during a two-hour exchange with 15 mL of 7% glucose3C). Also, treatment with L-NAME in rats with acute
supplemented (,) or not (,) with 5 mmol/L L-NAME. All parame-peritonitis induced a significant increase in the dialysate-
ters were obtained for 6 rats in each group. Acute peritonitis induces a
over-plasma ratio for osmolality at T30, from 2.29  0.02 significant increase in permeability for urea and glucose, and a loss of
sodium sieving (*P 
 0.05 vs. C). These modifications are significantly(P) to 2.34  0.02 (P-LA5) and further to 2.42  0.03
reduced when L-NAME is added to the dialysate (#P 
 0.05 vs. P).(P-LA10).
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The effect of L-NAME on UF was maximal at 2.5
mmol/L (Fig. 4A), whereas the effect on protein loss
and permeability for urea was dose-dependent and maxi-
mal at 10 mmol/L (Fig. 4 B, C).
DISCUSSION
This study used a well-characterized model of acute
peritonitis in rats to demonstrate that local generation
of NO, secondary to the up-regulation of NOS isoforms,
induces major, detrimental changes in peritoneal perme-
ability. These functional changes are partially reversed
by acute NOS inhibition, whereas structural modifica-
tions associated with the release of NO (formation of
S-nitrosocysteine) are not affected. In contrast, the lack
of functional consequences of NOS inhibition in control
rats suggests that NO does not influence significantly
peritoneal permeability in stable, uninfected PD.
Analogues of l-arginine can inhibit the production of
NO by NOS isoforms. L-NAME has proven to be one
of the most useful NOS inhibitors due to its low cost,
commercial availability, chemical stability, solubility in
water, and effectiveness in the millimolar range both
for tissue studies and in vivo investigations [13, 19, 20].
Because previous studies have shown that local, intra-
peritoneal production of NO might be critical for regulat-
ing PD parameters [7–9, 13], we postulated that adminis-
tration of L-NAME in the dialysate was probably more
relevant than systemic infusion, which induces acute and
severe hypertension [21]. Nevertheless, hemodynamic
monitoring revealed that rats treated with L-NAME in
the dialysate had a mild but consistent increase in systolic
blood pressure during the exchange, which contrasts with
the drop observed in absence of L-NAME (Table 1).
Addition of L-NAME to the dialysate did not induce
other clinical or biological side effects, and did not alter
the morphology of the peritoneum. In particular, mor-
phological examination confirmed the absence of conges-
tion, infarction, or infiltrate in control rats treated with
L-NAME.
A modified peritoneal equilibration test [9] was used
to investigate the effects of L-NAME on peritoneal per-
meability (Fig. 2A). Addition of 5 mmol/L L-NAME to
the dialysate in control rats did not affect UF and protein
loss in the dialysate significantly, and was not associated
Fig. 4. Effects of acute peritonitis and addition of L-NAME in the with permeability changes (Fig. 3). The lack of effect of
dialysate on ultrafiltration (A), protein loss (B), and urea permeability
NOS inhibition on the permeability for small solutes is(C ) during peritoneal dialysis in rats. (A) Net ultrafiltration (volume
out volume in, in mL). (B) Total protein concentration in the dialysate consistent with the results obtained in a chronic PD
(in g/L). (C) Cumulative urea permeability during the dwell (area under model in rabbits [14] and control Wistar rats [13]. Taken
the curve for the 120 min-dwell, in min) in control rats (C, ) and rats
together, these results suggest that the very low levelswith acute peritonitis (P), untreated () or treated ( ) with different
doses of L-NAME (2.5, 5 and 10 mmol/L) in the dialysate (*P 
 0.05 of bioactive NO generated by the peritoneum during
vs. C; #P 
 0.05 vs. P). stable uninfected PD [9, 12] do not critically affect perito-
neal permeability.
The situation is strikingly different in acute peritonitis.
In comparison with controls, rats with peritonitis were
Ferrier et al: NOS inhibition in acute peritonitis 2349
characterized by: structural modifications in the perito- and, via S-nitrosylation, regulate proteins such as recep-
neum (Fig. 1); up-regulation of eNOS and iNOS, paral- tors, enzymes, ion channels, and transcription factors
leled by increased NOS activities in the peritoneum (Fig. [24]. The concentration of S-nitrosocysteine reactivity in
2); increased permeability for urea and glucose, and loss endothelial cells (Fig. 1) might be relevant when consid-
of free-water permeability (Fig. 3); and the combination ering the potential interaction of NO with the critical
of decreased UF and increased protein loss in the dialy- cysteine 189 within aquaporin-1 (AQP1), the molecular
sate (Fig. 4). These changes, which confirm our previous counterpart of the ultrasmall pore in the endothelium
observations in this model [9], are characteristic of acute [25]. Indeed, recent structural data on AQP1 [26] confirm
peritonitis [2]. Furthermore, bacteriological findings in that this cysteine 189 is flanked by consensus motifs
rats with peritonitis are similar to the situation encoun- (acidic and/or basic residues) for S-nitrosylation [27].
tered in PD-related peritonitis, particularly in case of Arguably, the persistence of S-nitrosocysteine reactivity
touch contamination from skin flora [15]. implies that biochemical and/or structural conditions in-
Recent studies have suggested that increased EPSA volved in NO-induced modifications were not modified
and functional modifications observed in acute peritoni- by acute incubation with L-NAME. Finally, L-NAME
tis might be the consequence of increased NO production may inhibit constitutive NOS isoforms preferentially
mediated by the up-regulation of NOS isoforms in the over iNOS [28], which might explain its partial effect in
peritoneum [7–9]. This hypothesis was supported by the a situation characterized by the up-regulation of both
effect of L-NAME on peritoneal permeability for small eNOS and iNOS (Fig. 2). Studies in mouse models lack-
solutes and proteins in rats treated with lipopolysaccha- ing specific NOS isoforms will be necessary to delineate
rides from E. coli [13]. Our expression and enzymatic the precise involvement of each NOS isoform in the
studies (Figs. 1 and 2) confirm that peritonitis induces a pathophysiological changes observed.
major increase in NOS activity and up-regulates both Thus, our results demonstrate that inhibition of NOS
eNOS and iNOS in the peritoneum. As described earlier in the peritoneum during acute peritonitis significantly
[12], the induction of iNOS is variable in intensity and improves UF and reduces protein loss in the dialysate.
related to the severity of the peritonitis (as reflected by In view of the current effort to develop more specific
the WBC count in the dialysate). Furthermore, our re- NOS inhibitors [20], our observations suggest that this
sults provide direct evidence supporting the key role of type of drug may offer new therapeutic perspectives for
NO in that the addition of L-NAME to the dialysate functional alterations encountered during acute perito-
was sufficient to restore UF and decrease protein loss nitis.
during acute peritonitis (Fig. 4). This clinical benefit re-
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